Marksans Pharma Limited
NSE: MARKSANS BSE: MARKSANS
Prev Close
227.5
Open Price
228
Volume
3,372,266
Today Low / High
227.75 / 241
52 WK Low / High
171 / 358.7
Range
224 - 248
Prev Close
227.55
Open Price
228.55
Volume
212,949
Today Low / High
227.9 / 241
52 WK Low / High
168.05 / 358.5
Range
224 - 248
The stock is currently trading on both the National Stock Exchange (NSE) and Bombay Stock Exchange (BSE). On the NSE, the stock is priced at 236.25 (target range: 224 - 248), reflecting a change of 8.75 (3.84615%). On the BSE, it is listed at 236.15 (target range: 224 - 248), showing a change of 8.6 (3.77939%). Both the NSE and BSE data indicate positive movement, suggesting the stock is on an upward trend. This could be an attractive opportunity for investors looking for growth.
Marksans Pharma Limited Graph
Marksans Pharma Limited Price Target Predictions: Bullish vs. Bearish Scenarios with Ranges
If you are looking for the target price for Marksans Pharma Limited T1, T2, T3 for both Bullish and Bearish scenarios, here it is. For Bullish: T1, T2, T3. For Bearish: T1, T2, T3. The stock current price is 236.25, with potential price targets ranging from T1, T2, and T3 in both directions based on market conditions.
| Scenario | Price | Target | Range |
|---|---|---|---|
| Bullish Scenario | 236.15 | 238.51 | 214.66 - 262.36 |
| 240.87 | 192.70 - 289.05 | ||
| 243.23 | 170.26 - 316.20 | ||
| Bearish Scenario | 236.15 | 233.79 | 210.41 - 257.17 |
| 231.43 | 185.14 - 277.71 | ||
| 229.07 | 160.35 - 297.79 |
Overview of Marksans Pharma Limited
ISIN
INE750C01026
Industry
Drug Manufacturers - General
Vol.Avg
1,341,218
Market Cap
107,059,995,000
Last Dividend
0.6
Official Website
IPO Date
2002-07-19
DCF Diff
146.41
DCF
93
Financial Ratios Every Investor Needs
Stock Dividend of MARKSANS
| Date | Label | Adj Dividend | Dividend | Record Date | Payment Date | Declaration Date |
|---|---|---|---|---|---|---|
| 2025-08-01 | August 01, 25 | 0.8 | 0.8 | 2025-08-01 | 2025-08-21 | |
| 2024-09-17 | September 17, 24 | 0.6 | 0.6 | 2024-09-17 | 2024-10-05 | |
| 2023-06-07 | June 07, 23 | 0.5 | 0.5 | 2023-06-07 | 2023-09-27 | |
| 2022-08-19 | August 19, 22 | 0.25 | 0.25 | 2022-08-22 | 2022-09-28 | |
| 2021-09-15 | September 15, 21 | 0.25 | 0.25 | 2021-09-16 | 2021-10-23 |
Annual Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | R&D Expenses | G&A Expenses | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 2,622.85 Cr | 1,143.74 Cr | 1,479.10 Cr | 0.5639 | 0.00 Cr | 0.00 Cr | 1,128.80 Cr | 380.58 Cr | 8.40 | 528.64 Cr | 0.1451 |
| 2024-03-31 | 2,177.41 Cr | 1,094.24 Cr | 1,083.17 Cr | 0.4975 | 19.93 Cr | 17.70 Cr | 779.16 Cr | 313.70 Cr | 6.92 | 509.00 Cr | 0.1441 |
| 2023-03-31 | 1,852.14 Cr | 921.36 Cr | 930.78 Cr | 0.5025 | 15.89 Cr | 16.26 Cr | 287.73 Cr | 266.31 Cr | 6.41 | 398.63 Cr | 0.1438 |
| 2022-03-31 | 1,480.12 Cr | 748.02 Cr | 732.11 Cr | 0.4946 | 19.25 Cr | 24.80 Cr | 214.10 Cr | 184.57 Cr | 4.51 | 300.73 Cr | 0.1247 |
| 2021-03-31 | 1,368.37 Cr | 618.60 Cr | 749.78 Cr | 0.5479 | 12.87 Cr | 23.88 Cr | 309.22 Cr | 238.54 Cr | 5.76 | 346.30 Cr | 0.1743 |
Annual Financials Balance Sheet
| Date | C&C Equ. | Tot. Assets | Tot. Liab. | Stock. Equity | Tot. Debt | Net Debt | Inv. | PP&E (Net) | Curr. Def. Rev. | Non-Curr. Def. Rev. | LT Invest. | Curr. Liab. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 704.21 Cr | 3,239.63 Cr | 750.25 Cr | 2,466.9120 Cr | 321.91 Cr | -382.30 Cr | 845.52 Cr | 895.41 Cr | 0.00 Cr | 0.00 Cr | 3.57 Cr | 477.3390 Cr |
| 2024-03-31 | 403.28 Cr | 2,680.95 Cr | 595.05 Cr | 2,065.0540 Cr | 244.06 Cr | -159.22 Cr | 617.94 Cr | 693.22 Cr | 2.12 Cr | 0.00 Cr | 0.17 Cr | 389.8490 Cr |
| 2023-03-31 | 382.44 Cr | 2,190.39 Cr | 425.32 Cr | 1,745.1620 Cr | 122.95 Cr | -259.49 Cr | 484.74 Cr | 386.89 Cr | 41.90 Cr | 0.00 Cr | -333.24 Cr | 340.9900 Cr |
| 2022-03-31 | 346.26 Cr | 1,640.10 Cr | 417.13 Cr | 1,202.2700 Cr | 110.78 Cr | -235.48 Cr | 424.44 Cr | 342.29 Cr | 32.50 Cr | 0.00 Cr | -6.20 Cr | 356.2180 Cr |
| 2021-03-31 | 209.38 Cr | 1,228.25 Cr | 322.90 Cr | 886.4950 Cr | 34.10 Cr | -175.28 Cr | 404.32 Cr | 254.02 Cr | 41.03 Cr | 12.11 Cr | 0.84 Cr | 298.3994 Cr |
Annual Financials Cash Flow Statement
| Date | Operating Cash | Investing Cash | Financing Cash | Free Cash | Cash Change | Cash at End | CapEx | Income | Debt Repay | Dividends | Inventory |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 206.6640 Cr | -49.0090 Cr | -65.1460 Cr | 33.7450 Cr | 92.5090 Cr | 495.7860 Cr | -172.9190 Cr | 380.5750 Cr | -29.5650 Cr | -27.1900 Cr | -195.4670 Cr |
| 2024-03-31 | 230.4070 Cr | -140.8400 Cr | -68.7270 Cr | 21.5690 Cr | 20.8400 Cr | 403.2770 Cr | -208.8380 Cr | 313.7000 Cr | -12.4970 Cr | -22.6580 Cr | -112.6730 Cr |
| 2023-03-31 | 237.4120 Cr | -259.2120 Cr | 197.8290 Cr | 183.7810 Cr | 176.0310 Cr | 382.4370 Cr | -53.6310 Cr | 337.6530 Cr | 5.2960 Cr | -10.1710 Cr | -44.8500 Cr |
| 2022-03-31 | 99.2570 Cr | -41.6860 Cr | 79.5110 Cr | 52.9270 Cr | 137.0820 Cr | 349.2650 Cr | -46.3300 Cr | 247.5110 Cr | 22.5520 Cr | -10.5830 Cr | -17.8490 Cr |
| 2021-03-31 | 178.7409 Cr | -44.8959 Cr | -15.2859 Cr | 132.3169 Cr | 118.5591 Cr | 212.2862 Cr | -46.4240 Cr | 302.1641 Cr | -0.1030 Cr | -4.0930 Cr | -162.4758 Cr |
Quarterly Financial Income Report
| Date | Revenue | Co.Rev | GP | GPR | Operating Income | Net Income | EPS | EBITDA | NIR |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 708.46 Cr | 325.22 Cr | 383.24 Cr | 0.5409 | 286.02 Cr | 90.55 Cr | 2.00 | 123.86 Cr | 0.1278 |
| 2024-12-31 | 681.85 Cr | 298.34 Cr | 383.50 Cr | 0.5624 | 118.08 Cr | 104.56 Cr | 2.31 | 166.61 Cr | 0.1534 |
| 2024-09-30 | 641.92 Cr | 258.40 Cr | 383.53 Cr | 0.5975 | 116.17 Cr | 96.72 Cr | 2.13 | 146.74 Cr | 0.1507 |
| 2024-06-30 | 590.62 Cr | 362.71 Cr | 227.91 Cr | 0.3859 | 107.99 Cr | 88.75 Cr | 1.96 | 143.39 Cr | 0.1503 |
| 2024-03-31 | 560.01 Cr | 370.63 Cr | 189.39 Cr | 0.3382 | 88.59 Cr | 78.29 Cr | 1.73 | 126.17 Cr | 0.1398 |
Quarterly Financials Balance Sheet
| Date | Cash & Equiv. | Short-Term Inv. | Cash & Short-Term | Net Receivables | Inventory | Total Curr. Assets | PP&E (Net) | Total Assets | Total Liabilities |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 704.21 Cr | 0.74 Cr | 704.95 Cr | 540.04 Cr | 845.52 Cr | 2,204.12 Cr | 895.41 Cr | 3,239.63 Cr | 750.25 Cr |
| 2024-12-31 | 0.00 Cr | 0.00 Cr | 672.03 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | -2,305.12 Cr |
| 2024-09-30 | 380.97 Cr | 300.58 Cr | 681.55 Cr | 0.00 Cr | 758.35 Cr | 2,078.51 Cr | 686.09 Cr | 2,911.32 Cr | 606.20 Cr |
| 2024-06-30 | 0.00 Cr | 0.00 Cr | 700.57 Cr | 0.00 Cr | 0.00 Cr | 700.57 Cr | 0.00 Cr | 0.00 Cr | -2,085.91 Cr |
| 2024-03-31 | 673.58 Cr | 26.99 Cr | 700.57 Cr | 453.18 Cr | 617.94 Cr | 1,862.49 Cr | 681.09 Cr | 2,680.95 Cr | 595.05 Cr |
Quarterly Financials Cash Flow Statement
| Date | Net Income | Operating Cash Flow | Investing Cash Flow | Financing Cash Flow | Net Cash Change | Cash at End | Cash at Beginning | CapEx | Free Cash Flow |
|---|---|---|---|---|---|---|---|---|---|
| 2025-03-31 | 90.55 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-12-31 | 104.56 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-09-30 | 96.72 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-06-30 | 88.75 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
| 2024-03-31 | 78.29 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr | 0.00 Cr |
Splits History
| Date | Label | Split Ratio |
|---|---|---|
| 2008-03-11 | March 11, 08 | 10:1 |
Similar Stocks: Drug Manufacturers - General
| Company Name | Symbol | Price | Market Cap | Volume |
|---|---|---|---|---|
| Cipla Limited | CIPLA | ₹1,559.40 | ₹1,259,606,909,400.00 | ₹1,389,990.00 |
| Abbott India Limited | ABBOTINDIA | ₹35,195.00 | ₹747,869,113,500.00 | ₹8,866.00 |
| GlaxoSmithKline Pharmaceuticals Limited | GLAXO | ₹3,197.00 | ₹541,590,982,000.00 | ₹96,877.00 |
| Gland Pharma Limited | GLAND | ₹2,060.70 | ₹339,512,689,200.00 | ₹140,485.00 |
| Pfizer Limited | PFIZER | ₹5,260.50 | ₹240,655,775,850.00 | ₹16,259.00 |
| Sanofi India Limited | SANOFI | ₹5,881.00 | ₹135,439,430,000.00 | ₹6,018.00 |
| Marksans Pharma Limited | MARKSANS | ₹236.25 | ₹107,059,995,000.00 | ₹3,372,266.00 |
Key Executives
Gender: female
Year Born: 1971
Gender: male
Year Born: 1970
Gender: male
Year Born:
Gender: male
Year Born: 1972
Gender: male
Year Born:
Gender: male
Year Born:
Gender: male
Year Born: 1960
Gender: male
Year Born: 1970
Gender: male
Year Born: 1969
Gender: male
Year Born: 1969
FAQs about Marksans Pharma Limited
The CEO is Mark B. Saldanha.
The current price is ₹236.25.
The range is ₹171-358.7.
The market capitalization is ₹10,706.00 crores.
The dividend yield is 0.25%.
The P/E ratio is 28.10.
The company operates in the Healthcare sector.
Overview of Marksans Pharma Limited (ISIN: INE750C01026) is a leading Drug Manufacturers - General in India. With a market capitalization of ₹10,706.00 crores and an average daily volume of 1,341,218 shares, it operates in the Drug Manufacturers - General. The company last declared a dividend of ₹0.6.